CBD is well tolerated in humans with doses up to 600 mg not resulting in psychotic symptoms (15). In the few small placebo-controlled studies performed, no significant CNS effects were noted. Oral CBD undergoes extensive first-pass metabolism via CYP3A4, with a bioavailability of 6%. Following single doses in humans, the half-life of CBD when taken orally is about 1 to 2 days.1 In vitro studies have shown that CBD is a potent inhibitor of multiple CYP isozymes, including CYP 2C and CYP3A (16, 17). Whether these in vitro observations are relevant at plasma concentrations likely to be seen in patients is unclear. In addition, given its metabolism via CYP3A4, clinical trials of CBD in patients receiving enzyme-inducing AEDs, such as carbamazepine or phenytoin, will require detailed pharmacokinetic studies.
Because PharmaHemp’s first business is that of a supplier of raw materials, many of the micro brands you may have come across in Europe and beyond maybe white-labelling PharmaHemp’s CBD oil; in other words, they put their own stamp (branding and packaging) on PharmaHemp’s formulas or requested bespoke formulas. Why not just take it directly from the source? We like dealing with the main supplier directly, particularly in the case of PharmaHemp, who already has a very strong brand identity and ethos. We match their prices and import their products regularly to have the freshest batches of their stock available. Visit the PharmaHemp collection.
At this time, there does seem to be a growing body of basic pharmacologic data suggesting there may be a role for CBD, especially in the treatment of refractory epilepsy. However, given the lack of well-controlled trials, we must also ask if we are getting ahead of ourselves. Clearly, this is an emotionally and politically charged issue. If this were any other uninvestigated pharmaceutical compound, would we feel as compelled to make the agent widely available before statistically valid class 1 evidence was available for review? Until data from well-designed clinical trials are available and reliable, and standardized CBD products that are produced using GMP are available, caution must be exercised in any consideration of using CBD for the treatment of epilepsy. In the meantime, based upon promising preliminary data, further clinical research should be wholeheartedly pursued.
Hemplucid uses domestically sourced full-spectrum CBD to make this tincture. It includes a medium-chain triglyceride carrier MCT oil as part of the formula. This product contains terpenes and nearly undetectable levels of THC. The ingredients are all-natural, and they come from hemp plants that are bred for almost ten years to ensure a high level of cannabinoids. This product is certified as organic, and it does not contain GMOs.
CBD hemp oil has a huge range of potential health benefits and uses, including reducing pain, soothing anxiety, fighting chronic diseases, improving mood, eliminating depression, preventing inflammatory arthritis, protecting the immune system, balancing the metabolism, aiding sleep disorders, and healing the skin, among others. CBD oil can also be used in many different ways and has a variety of applications for natural health.